Maternal Selective Serotonin Reuptake Inhibitor Use during Pregnancy and Newborn Neurobehavior

Pediatrics

Volumn 113, Issue 2, 2004, Pages 368-375

  Zeskind, Philip Sanford ^a,b   Stephens, Laura E ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Heart rate variability; Maternal depression; Neurobehavior; Pregnancy; Sleep; SSRI

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; LITHIUM; OLANZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; BIRTH WEIGHT; CHILD BEHAVIOR; CLINICAL ARTICLE; COGNITION; DEPRESSION; DRUG EFFECT; FEMALE; GESTATIONAL AGE; HEART RATE VARIABILITY; HUMAN; MATERNAL AGE; MOTOR ACTIVITY; NEWBORN; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REM SLEEP; SLEEP; SMOKING; SOCIAL STATUS; STARTLE REFLEX;

ADULT; CASE-CONTROL STUDIES; ETHNIC GROUPS; FEMALE; GESTATIONAL AGE; HEART RATE; HUMANS; INFANT BEHAVIOR; INFANT, NEWBORN; MALE; MOTOR ACTIVITY; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SLEEP; SOCIOECONOMIC FACTORS; STARTLE REACTION; TREMOR;

EID: 0842346538     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.113.2.368     Document Type: Article

References (74)

1. Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Frank E. Pharmacologic treatment of depression during pregnancy. JAMA. 1999;282:1264-1269
2. Wisner KL, Peindl KP, Hanusa, BH. Relationship of psychiatric illness to childbearing status: a hospital-based epidemiologic study. J Affect Disord. 1993;28:39-50
3. O'Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Child Psychol. 1984;93:158-171
4. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ. 2001;323:257-260
5. Goldberg H, Nissim R. Psychotropic drugs in pregnancy and lactation. Int J Psychiatry Med. 1994;2:129-149
6. Emslie G, Judge R. Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatr Scand Suppl. 2000;403:26-34
7. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol. 1998;12(suppl 3-B):S55-S87
8. Hansson SR, Hoffman BJ, Mezey E. Serotonin transporter messenger RNA in the developing rat brain: early expression in serotonergic neurons and transient expression in non-serotonergic neurons. Neuroscience. 1998;83:1185-1200
9. Sarko J. Antidepressants, old and new. A review of their adverse effects and toxicity in overdose. Emerg Med Clin North Am. 2000;18:637-654
10. Hendrick V, Stowe Z, Altshuler L, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medication. Am J Psychiatry. 2003;160:993-996
11. Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM. Serotonin as a developmental signal. Behav Brain Res. 1996;73:19-29
12. Lauder JM. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci. 1993;16:233-240
13. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J. A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol. 1994;23:194-205
14. DeCeballos ML, Benedi A, Urdin C, Del Rio J. Prenatal exposure of rats to antidepressant drugs down-regulates beta-adrenoceptors and 5-HT2 receptors in cerebral cortex: lack of correlation between 5-HT2 receptors and serotonin-mediated behaviour. Neuropharmacology. 1985;24:947-952
15. Jason KM, Cooper TB, Friedman E. Prenatal exposure to imipramine alters early behavioral development and beta adrenergic receptors in rats. J Pharmacol Exp Ther. 1981;217:461-466
16. Wisner KL, Zarin D, Holmboe E, et al. Risk-Benefit decision making for treatment of depression during pregnancy. Am J Psychiatry. 2000;157:1933-1940
17. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159:2055-2061
18. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry. 2000;48:996-1000
19. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015
20. Kent L, Laidlaw J. Suspected congenital sertraline dependence. Br J Psychiatry. 1995;167:412-413 (letter)
21. Spencer M. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics. 1993;92:721-722
22. Stiskal JA, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child. 2001;84:F134-F135
23. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry. 1997;171:391-392
24. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry. 1993;32:1253-1255
25. Oberlander TF, Eckstein Grunau R, Fitzgerald C, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res. 2002;51:443-453
26. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics. 2000;105:880-887
27. Singer LT, Zeskind PS. Biobehavioral Assessment of the Infant. New York, NY: Guilford Press; 2001
28. Prechtl HFR, Beintema D. The neurological examination of the full-term infants. In: Clinics in Developmental Medicine. No. 12. Philadelphia, PA: Lippincott; 1964
29. Wolff PH. The Causes, Controls, and Organization of Behavior in the Neonate. New York, NY: International Universities Press; 1966
30. Brazelton TB. Neonatal Behavioral Assessment Scale. 2nd ed. Philadelphia, PA: Spastics International Medical Publications; 1984
31. Lester BM, Tronick EZ. Behavioral Assessment Scales - The NICU Network Neurobehavioral Scale, the Neonatal Behavioral Assessment Scale, and the Assessment of the Preterm Infant's Behavior. In: Singer LT, Zeskind PS, eds. Biobehavioral Assessment of the Infant. New York, NY: The Guilford Press; 2001:363-380
32. Thoman EB. Sleep-wake states as context for assessment, as components of assessment, and as assessment. In: Singer LT, Zeskind PS, eds. Biobehavioral Assessment of the Infant. New York, NY: The Guilford Press; 2001:125-148
33. Zeskind PS, Marshall TR, Goff DM. Rhythmic organization of heart rate in breast-fed and bottle-fed newborn infants. Early Dev Parenting. 1992;1:79-87
34. Zeskind PS, Goff DM, Marshall TR. Rhythmic organization of neonatal heart rate and its relation to atypical fetal growth. Dev Psychobiol. 1991;24:413-429
35. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001;24:183-197
36. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16:356-362
37. Huntington L, Zeskind PS, Weiseman JR. Spontaneous startle activity in newborn infants. Int Behav Dev. 1985;8:301-308
38. Zeskind PS, Marshall TR, Goff DM. Cry threshold predicts regulatory disorder in newborn infants. J Pediatr Psychol. 1996;21:803-819
39. Lester BM, Als H, Brazelton TB. Regional obstetric anesthesia and newborn behavior: a reanalysis toward synergistic effects. Child Dev. 1982;53:687-692
40. Robertson SS, Dierker LJ. The development of cyclic motility in fetuses of diabetic mothers. Dev Psychobiol. 1986;19:223-234
41. Porter FL. Vagal tone. In: Singer L, Zeskind P, eds. Biobehavioral Assessment of the Infant. New York, NY: Guilford Publications; 2001:109-124
42. Zeskind PS, Marshall TR. Temporal organization in neonatal arousal: systems, oscillations, and development. In: Weiss M, Zelazo P, eds. Newborn Attention: Biological Constraints and Influence of Experience. Norwood, NJ: Ablex; 1991:22-62
43. Porges SW. Heart rate patterns in neonates: a potential diagnostic window to the brain. In: Field TM, Sostek A, eds. Infants Born at Risk. New York, NY: Grune & Stratton; 1983:3-22
44. Richards JE, Cameron D. Infant heart-rate variability and behavioral developmental status. Int Behav Dev. 1989;12:45-58
45. Jenkins GM, Watts DG. Spectral Analysis and Its Applications. San Francisco, CA: Holden-Day; 1968
46. Porges SW, Arnold WR, Forbes EJ. Heart rate variability: an index of attentional responsivity in human newborns. Dev Psychol. 1973;8:85-92
47. Lester BM, Tronick E, LaGasse L, et al. The maternal lifestyle study (MLS): effects of substance exposure during pregnancy on neurodevelopmental outcome in 1-month-old infants. Pediatrics. 2002;110:1182-1192
48. Law KL, Stroud LR, LaGasse L, Niaura R, Liu J, Lester BM. Smoking during pregnancy and newborn neurobehavior. Pediatrics. 2003;111 (suppl):1318-1323
49. Sandman C, Wadhwa P, Dunkel-Schetter C. Psychobiological influences of stress and HPA regulation on the human fetus and infant birth outcomes. Ann N Y Acad Sci. 1994;739:198-210
50. Van den Bergh B. Maternal emotions during pregnancy and fetal and neonatal behavior. In: Nijhuis JG, ed. Fetal Behaviour. Oxford, England: Oxford University Press; 1992:157-178
51. Allister L, Lester BM, Carr S, Liu J. The effects of maternal depression on fetal heart rate response to vibroacoustic stimulation. Dev Neuropsychol. 2001;20:639-651
52. Lundy B, Jones N, Field T, et al. Prenatal depression effects on neonates. Infant Behav Dev. 1999;22:119-129
53. Field T. Touch in Early Development. Mahwah, NJ: Lawrence Erlbaum; 1995
54. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269:2246-2248
55. Ericson A, Kallen B, Wiholm BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 1999;55:503-508
56. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol. 1995;15:417-420
57. Kulin N, Pastuszak A, Sage S, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA. 1998;279:609-610
58. Loebstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the motherisk experience. J Psychiatry Neurosci. 1997;22:192-196
59. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336:258-262
60. Nulman I, Rovet J, Stewart D, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159:1889-1895
61. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142:402-408
62. Eyler FD, Behnke M, Conlon M, Woods NS, Wobie K. Birth outcome from a prospective, matched study of prenatal crack/cocaine use: II. Interactive and dose effects on neurobehavioral assessment. Pediatrics. 1998;101:237-241
63. Lester BM, Corwin MJ, Sepkoski C, et al. Neurobehavioral syndromes in cocaine-exposed newborn infants. Child Dev. 1991;62:694-705
64. Coles CD, Platzman KA, Smith I, James ME, Falek A. Effects of cocaine and alcohol use in pregnancy on neonatal growth and neurobehavioral status. Neurotoxicol Teratol. 1992;14:23-33
65. Black M, Schuler M, Nair P. Prenatal drug exposure: neurodevelopmental outcome and parenting environment. J Pediatr Psychol. 1993;18:605-620
66. Schatzberg AF, Haddad PM, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. J Clin Psychiatry. 1997;58(suppl 7):23-27
67. Case-Smith J, Bigsby R. Motor assessment. In: Singer LT, Zeskind PS, eds. Biobehavioral Assessment of the Infant. New York, NY: The Guilford Press; 2001:423-442
68. Jacobs BL, A FC. 5HT and motor control: a hypothesis. Trends Neurosci. 1993;16:346-352
69. Kakebeeke TH, von Siebenthal K, Largo RH. Movement quality in preterm infants prior to term. Biol Neonate. 1998;73:145-154
70. Berg WK, Berg KM. Psychophysiological development in infancy: state, startle, and attention. In: Osofsky J, ed. Handbook of Infant Development. 2nd ed. New York, NY: Wiley; 1987:238-317
71. Zeskind PS, O'Grady C, Tremblay N. Psychosocial intervention in mothers improves autonomic regulation of preterm infants in the NICU. Presented at the Society for Pediatric Research; April 2001; Baltimore, MD
72. Isbister GK, Dawson A, Whyte I, Prior F, Clancy C, Smith A. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child. 2001;85:F145
73. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol. 1997;17:208-221
74. Mayes LC, Grillon C, Granger R, Schottenfeld R. Regulation of arousal and attention in preschool children exposed to cocaine prenatally. In: Boland BM, Cullinan J, Fink AC, eds. Cocaine: Effects on the Developing Brain. New York, NY: The New York Academy of Sciences; 1998:126-143